tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks Momentum IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsMost Visited Websites
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Novo Nordisk (DE:NOV)
XETRA:NOV
Germany Market
NOV
Novo Nordisk
Overview
Analyst Forecasts
Dividends
Earnings
Financials
Statistics
New
Technical Analysis
Historical Prices
New
News & Insights
Chart
RESEARCH TOOLS
Top Analyst Stocks
Top Smart Score Stocks
Stock Screener
reports

Novo Nordisk (NOV) Stock Forecast & Price Target

Compare
304 Followers
See the Price Targets and Ratings of:

NOV Analyst Ratings

Moderate Buy
13Ratings
7 Buy
5 Hold
1 Sell
Based on 13 analysts giving stock ratings to
Novo
Nordisk
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

NOV Stock 12 Month Forecast

Average Price Target

€96.02
▲(75.96% Upside)
Based on 13 Wall Street analysts offering 12 month price targets for Novo Nordisk in the last 3 months. The average price target is €96.02 with a high forecast of €133.90 and a low forecast of €55.57. The average price target represents a 75.96% change from the last price of €54.57.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"54":"€54","74":"€74","94":"€94","114":"€114","134":"€134"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":133.903,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€133.90</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":96.01916324,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€96.02</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":55.569745,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€55.57</span>\n  </div></div>","useHTML":true}}],"tickPositions":[54,74,94,114,134],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2024","6":"Oct<br/>2024","9":"Jan<br/>2025","12":"Apr<br/>2025","25":"Apr<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,64.13,69.49715384615384,74.86430769230769,80.23146153846153,85.59861538461539,90.96576923076923,96.33292307692307,101.70007692307692,107.06723076923076,112.4343846153846,117.80153846153846,123.1686923076923,128.53584615384614,{"y":133.903,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,64.13,66.58301255692307,69.03602511384615,71.48903767076922,73.9420502276923,76.39506278461538,78.84807534153846,81.30108789846153,83.75410045538462,86.20711301230769,88.66012556923077,91.11313812615384,93.56615068307693,{"y":96.01916324,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,64.13,63.47151884615384,62.81303769230769,62.154556538461534,61.49607538461538,60.83759423076923,60.17911307692307,59.52063192307692,58.862150769230766,58.20366961538461,57.54518846153846,56.886707307692305,56.22822615384615,{"y":55.569745,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":114.304,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":117.381,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":121.634,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":132.904,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":120.811,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":122.32,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":104.967,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":101.524,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":102.016,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":82.37,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":80.294,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":85.016,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":64.13,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€133.90Average Price Target€96.02Lowest Price Target€55.57
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
xxxxxxxxxxxxxxxxxx
UBS
UBS
xxxxxxxxxxxxx
xxxxxxxxxxxxx
xxxxxxxxxxxxx
Reiterated
04/08/25
xxxxxxxxxxxxx
xxxxxxxxxxxxx
xxxxxxxxxxxxxxxxxx
Deutsche Bank
Deutsche Bank
xxxxxxxxxxxxx
xxxxxxxxxxxxx
xxxxxxxxxxxxx
Reiterated
04/07/25
xxxxxxxxxxxxx
xxxxxxxxxxxxx
xxxxxxxxxxxxxxxxxx
Bernstein
Bernstein
xxxxxxxxxxxxx
xxxxxxxxxxxxx
xxxxxxxxxxxxx
Reiterated
04/07/25
xxxxxxxxxxxxx
xxxxxxxxxxxxx
xxxxxxxxxxxxxxxxxx
Jefferies
Jefferies
xxxxxxxxxxxxx
xxxxxxxxxxxxx
xxxxxxxxxxxxx
Reiterated
04/03/25
xxxxxxxxxxxxx
xxxxxxxxxxxxx
xxxxxxxxxxxxxxxxxx
Goldman Sachs
Goldman Sachs
xxxxxxxxxxxxx
xxxxxxxxxxxxx
xxxxxxxxxxxxx
Reiterated
04/03/25
xxxxxxxxxxxxx
xxxxxxxxxxxxx
xxxxxxxxxxxxxxxxxx
J.P. Morgan
J.P. Morgan
xxxxxxxxxxxxx
xxxxxxxxxxxxx
xxxxxxxxxxxxx
Reiterated
03/28/25
xxxxxxxxxxxxx
xxxxxxxxxxxxx
xxxxxxxxxxxxxxxxxx
Bank of America Securities
Bank of America Securities
xxxxxxxxxxxxx
xxxxxxxxxxxxx
xxxxxxxxxxxxx
Reiterated
03/28/25
xxxxxxxxxxxxx
xxxxxxxxxxxxx
xxxxxxxxxxxxxxxxxx
Morgan Stanley
Morgan Stanley
xxxxxxxxxxxxx
xxxxxxxxxxxxx
xxxxxxxxxxxxx
Reiterated
03/27/25
xxxxxxxxxxxxx
xxxxxxxxxxxxx
xxxxxxxxxxxxxxxxxx
Berenberg Bank
Berenberg Bank
xxxxxxxxxxxxx
xxxxxxxxxxxxx
xxxxxxxxxxxxx
Reiterated
03/24/25
xxxxxxxxxxxxx
xxxxxxxxxxxxx
xxxxxxxxxxxxxxxxxx
Kepler Capital
Kepler Capital
xxxxxxxxxxxxx
xxxxxxxxxxxxx
xxxxxxxxxxxxx
Upgraded
03/13/25
xxxxxxxxxxxxx
xxxxxxxxxxxxx
Stifel Nicolaus Analyst forecast on DE:NOV
Eric Le Berrigaud
Stifel Nicolaus
€104.46→€93.75
Hold
71.80%
Upside
Downgraded
03/03/25
Novo Nordisk downgraded to Hold from Buy at StifelNovo Nordisk downgraded to Hold from Buy at Stifel
DZ BANK AG Analyst forecast on DE:NOV
Elmar Kraus
DZ BANK AG
―
Hold
―
Reiterated
02/06/25
DZ BANK AG Sticks to Their Hold Rating for Novo Nordisk (0QIU)
Guggenheim Analyst forecast on DE:NOV
Seamus Fernandez
Guggenheim
€106.47→€106.87
Buy
95.85%
Upside
Reiterated
01/17/25
Novo Nordisk price target raised to DKK 798 from DKK 795 at GuggenheimNovo Nordisk price target raised to DKK 798 from DKK 795 at Guggenheim
Handelsbanken Capital Analyst forecast on DE:NOV
Mattias Haggblom
Handelsbanken Capital
€133.93
Buy
145.42%
Upside
Upgraded
12/23/24
Novo Nordisk upgraded to Outperform from Market Perform at HandelsbankenNovo Nordisk upgraded to Outperform from Market Perform at Handelsbanken
Barclays Analyst forecast on DE:NOV
Emily Field
Barclays
€140.62→€120.54
Buy
120.88%
Upside
Reiterated
12/23/24
Novo Nordisk price target lowered to DKK 900 from DKK 1,050 at BarclaysNovo Nordisk price target lowered to DKK 900 from DKK 1,050 at Barclays
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
xxxxxxxxxxxxxxxxxx
UBS
UBS
xxxxxxxxxxxxx
xxxxxxxxxxxxx
xxxxxxxxxxxxx
Reiterated
04/08/25
xxxxxxxxxxxxx
xxxxxxxxxxxxx
xxxxxxxxxxxxxxxxxx
Deutsche Bank
Deutsche Bank
xxxxxxxxxxxxx
xxxxxxxxxxxxx
xxxxxxxxxxxxx
Reiterated
04/07/25
xxxxxxxxxxxxx
xxxxxxxxxxxxx
xxxxxxxxxxxxxxxxxx
Bernstein
Bernstein
xxxxxxxxxxxxx
xxxxxxxxxxxxx
xxxxxxxxxxxxx
Reiterated
04/07/25
xxxxxxxxxxxxx
xxxxxxxxxxxxx
xxxxxxxxxxxxxxxxxx
Jefferies
Jefferies
xxxxxxxxxxxxx
xxxxxxxxxxxxx
xxxxxxxxxxxxx
Reiterated
04/03/25
xxxxxxxxxxxxx
xxxxxxxxxxxxx
xxxxxxxxxxxxxxxxxx
Goldman Sachs
Goldman Sachs
xxxxxxxxxxxxx
xxxxxxxxxxxxx
xxxxxxxxxxxxx
Reiterated
04/03/25
xxxxxxxxxxxxx
xxxxxxxxxxxxx
xxxxxxxxxxxxxxxxxx
J.P. Morgan
J.P. Morgan
xxxxxxxxxxxxx
xxxxxxxxxxxxx
xxxxxxxxxxxxx
Reiterated
03/28/25
xxxxxxxxxxxxx
xxxxxxxxxxxxx
xxxxxxxxxxxxxxxxxx
Bank of America Securities
Bank of America Securities
xxxxxxxxxxxxx
xxxxxxxxxxxxx
xxxxxxxxxxxxx
Reiterated
03/28/25
xxxxxxxxxxxxx
xxxxxxxxxxxxx
xxxxxxxxxxxxxxxxxx
Morgan Stanley
Morgan Stanley
xxxxxxxxxxxxx
xxxxxxxxxxxxx
xxxxxxxxxxxxx
Reiterated
03/27/25
xxxxxxxxxxxxx
xxxxxxxxxxxxx
xxxxxxxxxxxxxxxxxx
Berenberg Bank
Berenberg Bank
xxxxxxxxxxxxx
xxxxxxxxxxxxx
xxxxxxxxxxxxx
Reiterated
03/24/25
xxxxxxxxxxxxx
xxxxxxxxxxxxx
xxxxxxxxxxxxxxxxxx
Kepler Capital
Kepler Capital
xxxxxxxxxxxxx
xxxxxxxxxxxxx
xxxxxxxxxxxxx
Upgraded
03/13/25
xxxxxxxxxxxxx
xxxxxxxxxxxxx
Stifel Nicolaus Analyst forecast on DE:NOV
Eric Le Berrigaud
Stifel Nicolaus
€104.46→€93.75
Hold
71.80%
Upside
Downgraded
03/03/25
Novo Nordisk downgraded to Hold from Buy at StifelNovo Nordisk downgraded to Hold from Buy at Stifel
DZ BANK AG Analyst forecast on DE:NOV
Elmar Kraus
DZ BANK AG
―
Hold
―
Reiterated
02/06/25
DZ BANK AG Sticks to Their Hold Rating for Novo Nordisk (0QIU)
Guggenheim Analyst forecast on DE:NOV
Seamus Fernandez
Guggenheim
€106.47→€106.87
Buy
95.85%
Upside
Reiterated
01/17/25
Novo Nordisk price target raised to DKK 798 from DKK 795 at GuggenheimNovo Nordisk price target raised to DKK 798 from DKK 795 at Guggenheim
Handelsbanken Capital Analyst forecast on DE:NOV
Mattias Haggblom
Handelsbanken Capital
€133.93
Buy
145.42%
Upside
Upgraded
12/23/24
Novo Nordisk upgraded to Outperform from Market Perform at HandelsbankenNovo Nordisk upgraded to Outperform from Market Perform at Handelsbanken
Barclays Analyst forecast on DE:NOV
Emily Field
Barclays
€140.62→€120.54
Buy
120.88%
Upside
Reiterated
12/23/24
Novo Nordisk price target lowered to DKK 900 from DKK 1,050 at BarclaysNovo Nordisk price target lowered to DKK 900 from DKK 1,050 at Barclays
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxx
xxx
xxx
xxx
xxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Novo Nordisk

Which Analyst Should I Follow If I Want to Buy DE:NOV and Sell After:
1 Month
xxx
Success Rate
11/16 ratings generated profit
69%
Average Return
+3.95%
reiterated a xxx
 rating 7 months ago
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 1 Month would result in 68.75% of your transactions generating a profit, with an average return of +3.95% per trade.
3 Months
xxx
Success Rate
12/16 ratings generated profit
75%
Average Return
+4.56%
reiterated a xxx
 rating 7 months ago
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 3 Months would result in 75.00% of your transactions generating a profit, with an average return of +4.56% per trade.
1 Year
Emily FieldBarclays
Success Rate
24/32 ratings generated profit
75%
Average Return
+23.38%
reiterated a buy rating 4 months ago
Copying Emily Field's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +23.38% per trade.
2 Years
xxx
Success Rate
33/55 ratings generated profit
60%
Average Return
+22.59%
reiterated a xxx
 rating 15 days ago
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 2 Years would result in 60.00% of your transactions generating a profit, with an average return of +22.59% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

NOV Analyst Recommendation Trends

Rating
Dec 24
Jan 25
Feb 25
Mar 25
Apr 25
Strong Buy
1
9
14
20
16
Buy
24
29
26
25
15
Hold
20
19
19
17
14
Sell
7
8
8
4
3
Strong Sell
0
0
0
0
0
total
52
65
67
66
48
In the current month, NOV has received 31 Buy Ratings, 14 Hold Ratings, and 3 Sell Ratings. NOV average Analyst price target in the past 3 months is €96.02.
Each month's total comprises the sum of three months' worth of ratings.

NOV Financial Forecast

NOV Earnings Forecast

Next quarter’s earnings estimate for NOV is €0.84 with a range of €0.80 to €0.94. The previous quarter’s EPS was €0.85. NOV beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.47% of the time in the same period. In the last calendar year NOV has Outperformed its overall industry.
Next quarter’s earnings estimate for NOV is €0.84 with a range of €0.80 to €0.94. The previous quarter’s EPS was €0.85. NOV beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.47% of the time in the same period. In the last calendar year NOV has Outperformed its overall industry.

NOV Sales Forecast

Next quarter’s sales forecast for NOV is €10.61B with a range of €10.17B to €11.13B. The previous quarter’s sales results were €11.48B. NOV beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 46.82% of the time in the same period. In the last calendar year NOV has Outperformed its overall industry.
Next quarter’s sales forecast for NOV is €10.61B with a range of €10.17B to €11.13B. The previous quarter’s sales results were €11.48B. NOV beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 46.82% of the time in the same period. In the last calendar year NOV has Outperformed its overall industry.

NOV Stock Forecast FAQ

What is DE:NOV’s average 12-month price target, according to analysts?
Based on analyst ratings, Novo Nordisk’s 12-month average price target is €96.02.
    What is DE:NOV’s upside potential, based on the analysts’ average price target?
    Novo Nordisk has 75.96% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Novo Nordisk a Buy, Sell or Hold?
          Novo Nordisk has a consensus rating of Moderate Buy, which is based on 7 buy ratings, 5 hold ratings and 1 sell ratings.
            What is Novo Nordisk’s share price target?
            The average share price target for Novo Nordisk is €96.02. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €133.90 ,and the lowest forecast is €55.57. The average share price target represents 75.96% Increase from the current price of €54.57.
              What do analysts say about Novo Nordisk?
              Novo Nordisk’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 13 Wall Streets Analysts.
                How can I buy shares of Novo Nordisk?
                To buy shares of DE:NOV, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

                  Become an Expert with TipRanks Premium

                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis
                  Subscribe NowSee Plans & Pricing